REG - Cambridge Cognition - Issue of Warrants

Cambridge Cognition HoldingsAnnouncement

05/10/2023 17:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231005:nRSE8898Oa&default-theme=true

RNS Number : 8898O  Cambridge Cognition Holdings PLC  05 October 2023

5 October 2023

Cambridge Cognition Holdings Plc

 

("Cambridge Cognition", the "Group" or the "Company")

 

Issue of Warrants

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets
digital solutions to assess brain health, announces, further to the Company's
announcement on 26 September 2023, that the Company has issued Claret European
Specialty Lending Company III, S.à r.l. ("Claret") with warrants to subscribe
for 722,565 new ordinary shares of 1 pence each in the capital of the Company
("Ordinary Shares") at an exercise price of 74.734p.

 

Enquiries

 

 Cambridge Cognition Holdings Plc                           Tel: 012 2381 0700 

 Matthew Stork, Chief Executive Officer                     press@camcog.com (mailto:press@camcog.com)  

 Stephen Symonds, Chief Financial Officer 

 Panmure Gordon (UK) Limited (NOMAD and Joint Broker)       Tel: 020 7886 2500 

 Freddy Crossley / Emma Earl / Mark Rodgers                 (Corporate Finance) 

 Rupert Dearden                                             (Corporate Broking) 

 Dowgate Capital Limited (Joint Broker)                     Tel: 020 3903 7715 

 David Poutney / James Serjeant                              

 IFC Advisory Ltd (Financial PR and IR)                     Tel: 020 3934 6630 

 Tim Metcalfe / Graham Herring / Zach Cohen                  cog@investor-focus.co.uk

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBLBDGDXGDGXU